enGene Therapeutics Inc

ENGN Healthcare Biotechnology

In the quarter to July 2026, EPS grew 18.2%, free cash flow grew 28.1% and total debt rose 42.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.67 0.04 −2.34%
Market cap
$114.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jul '26 Apr '26 Jan '26 Oct '25 Older periods
Current Ratio
10.21 12.57 11.75 6.30

+8 more quarters

Net Debt/EBITDA
7.07 7.24 7.96 4.49
Debt/Equity
0.11 0.10 0.09 0.09
Free Cash Flow per Share
(0.27) (0.44) (0.43) (0.50)
Book value per Share
3.30 3.66 4.19 3.28
Free Cash Flow
(18.95) (30.60) (29.06) (25.40)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026